Cargando…
Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG)
PURPOSE: To report on the clinical characteristics, outcome, and frequency of peritoneal carcinosis (PC) in patients with advanced germ cell tumors (GCT), a multicenter registry analysis was carried out. METHODS: A multicenter registry analysis was conducted by the German Testicular Cancer Study Gro...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921103/ https://www.ncbi.nlm.nih.gov/pubmed/34993564 http://dx.doi.org/10.1007/s00345-021-03905-0 |
_version_ | 1784669264857268224 |
---|---|
author | Seidel, Christoph Hentrich, Marcus Zschäbitz, Stefanie Paffenholz, Pia Heidenreich, Axel Nestler, Tim Tran, Ben Fischer, Stefanie Daugaard, Gedske Ochsenreither, Sebastian Brito, Margarida Zengerling, Friedemann Schwab, Constantin Bokemeyer, Carsten Oing, Christoph |
author_facet | Seidel, Christoph Hentrich, Marcus Zschäbitz, Stefanie Paffenholz, Pia Heidenreich, Axel Nestler, Tim Tran, Ben Fischer, Stefanie Daugaard, Gedske Ochsenreither, Sebastian Brito, Margarida Zengerling, Friedemann Schwab, Constantin Bokemeyer, Carsten Oing, Christoph |
author_sort | Seidel, Christoph |
collection | PubMed |
description | PURPOSE: To report on the clinical characteristics, outcome, and frequency of peritoneal carcinosis (PC) in patients with advanced germ cell tumors (GCT), a multicenter registry analysis was carried out. METHODS: A multicenter registry analysis was conducted by the German Testicular Cancer Study Group (GTCSG) with international collaborators. Data was collected and analyzed retrospectively. Patients were eligible for inclusion if PC was diagnosed either by radiologic or histopathologic finding during the course of disease. Descriptive and explorative statistical analysis was carried out with cancer-specific survival (CSS) as primary study endpoint. RESULTS: Collaborators from ten GCT expert centers identified 28 GCT (0.77%) patients with PC after screening approximately 3767 GCT patient files and one case was contributed from a cancer registry request. Patients were diagnosed from 1997 to 2019 at a median age of 37 years (interquartile range, 13). Two patients (7%) presented with stage I and 27 patients (93%) with synchronous metastatic disease at first diagnosis. The primary histology was seminoma in seven (27%) and non-seminoma in 21 patients (72%). PC was detected after a median of 15.3 months from primary diagnosis (range 0–177) and two consecutive treatment lines (range 0–5), respectively. The median CSS from the time of detection of PC was 10.5 months (95%Confidence Interval 0.47–1.30) associated with an overall 2-year CSS rate of 30%. CONCLUSION: PC represents a rare tumor manifestation in GCT patients and was primarily associated with the occurrence of advanced cisplatin-refractory disease conferring to a dismal prognosis. |
format | Online Article Text |
id | pubmed-8921103 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89211032022-03-17 Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) Seidel, Christoph Hentrich, Marcus Zschäbitz, Stefanie Paffenholz, Pia Heidenreich, Axel Nestler, Tim Tran, Ben Fischer, Stefanie Daugaard, Gedske Ochsenreither, Sebastian Brito, Margarida Zengerling, Friedemann Schwab, Constantin Bokemeyer, Carsten Oing, Christoph World J Urol Topic Paper PURPOSE: To report on the clinical characteristics, outcome, and frequency of peritoneal carcinosis (PC) in patients with advanced germ cell tumors (GCT), a multicenter registry analysis was carried out. METHODS: A multicenter registry analysis was conducted by the German Testicular Cancer Study Group (GTCSG) with international collaborators. Data was collected and analyzed retrospectively. Patients were eligible for inclusion if PC was diagnosed either by radiologic or histopathologic finding during the course of disease. Descriptive and explorative statistical analysis was carried out with cancer-specific survival (CSS) as primary study endpoint. RESULTS: Collaborators from ten GCT expert centers identified 28 GCT (0.77%) patients with PC after screening approximately 3767 GCT patient files and one case was contributed from a cancer registry request. Patients were diagnosed from 1997 to 2019 at a median age of 37 years (interquartile range, 13). Two patients (7%) presented with stage I and 27 patients (93%) with synchronous metastatic disease at first diagnosis. The primary histology was seminoma in seven (27%) and non-seminoma in 21 patients (72%). PC was detected after a median of 15.3 months from primary diagnosis (range 0–177) and two consecutive treatment lines (range 0–5), respectively. The median CSS from the time of detection of PC was 10.5 months (95%Confidence Interval 0.47–1.30) associated with an overall 2-year CSS rate of 30%. CONCLUSION: PC represents a rare tumor manifestation in GCT patients and was primarily associated with the occurrence of advanced cisplatin-refractory disease conferring to a dismal prognosis. Springer Berlin Heidelberg 2022-01-07 2022 /pmc/articles/PMC8921103/ /pubmed/34993564 http://dx.doi.org/10.1007/s00345-021-03905-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Topic Paper Seidel, Christoph Hentrich, Marcus Zschäbitz, Stefanie Paffenholz, Pia Heidenreich, Axel Nestler, Tim Tran, Ben Fischer, Stefanie Daugaard, Gedske Ochsenreither, Sebastian Brito, Margarida Zengerling, Friedemann Schwab, Constantin Bokemeyer, Carsten Oing, Christoph Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title | Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title_full | Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title_fullStr | Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title_full_unstemmed | Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title_short | Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG) |
title_sort | peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the german testicular cancer study group (gtcsg) |
topic | Topic Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8921103/ https://www.ncbi.nlm.nih.gov/pubmed/34993564 http://dx.doi.org/10.1007/s00345-021-03905-0 |
work_keys_str_mv | AT seidelchristoph peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT hentrichmarcus peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT zschabitzstefanie peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT paffenholzpia peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT heidenreichaxel peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT nestlertim peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT tranben peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT fischerstefanie peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT daugaardgedske peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT ochsenreithersebastian peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT britomargarida peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT zengerlingfriedemann peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT schwabconstantin peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT bokemeyercarsten peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg AT oingchristoph peritonealcarcinosisinmalegermcelltumorpatientsaregistrystudycompiledbythegermantesticularcancerstudygroupgtcsg |